At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antithrombotics
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Oct 1999 No-Development-Reported for Thrombosis in Germany (Unknown route)
- 25 Sep 1995 New profile
- 25 Sep 1995 Phase-II clinical trials for Thrombosis in Germany (Unknown route)